AUTHORS
Tian Zeng, Xiudi Yang2, Rumeng Li3, Qingmei Han4, Bingbing Wen5, Jian Huang, MD, PhD6
AFFILIATIONS
1 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
2 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
3 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
4 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
5 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
6 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
ABSTRACT
Introduction: Resistance or intolerance to ruxolitinib remains a major clinical challenge. Gecacitinib, a JAK/ACVR1 inhibitor, has been approved for the treatment of intermediate- or high-risk MF and has demonstrated potential benefits in controlling splenomegaly and constitutional symptoms, with a unique ability to improve anemia. However, real-world evidence regarding the effectiveness of gecacitinib after ruxolitinib failure remains limited. We therefore evaluated the clinical outcomes and predictors of response to gecacitinib in patients with MF after ruxolitinib failure.
Methods: This study retrospectively analyzed 55 patients who received Gecacitinib after ruxolitinib failure by assessing spleen, symptom, and anemia responses, and safety. Responses were assessed at 3 and 6 months after initiation of gecacitinib. Anemia response (AR) was defined according to updated European Leukemia Net (ELN) criteria. Logistic regression analyses identified the anemia responses’ predictors.
Results: Fifty-five patients with ruxolitinib failure were included (median age, 65.0 years), representing a high-risk population with substantial disease burden. The median hemoglobin level was 72.0 g/L, 40.0% of patients were transfusion-dependent, 34.6% had abnormal karyotypes, and high-molecular-risk mutations were identified in 59.5% of evaluable patients. All patients had received prior ruxolitinib therapy for a median duration of 12.0 months, with discontinuation due to intolerance (56.4%), resistance (20.0%), or both (23.6%).
Gecacitinib was initiated at the recommended dose in 52.7% of patients, and dose intensity increased during follow-up, with 76.5% of patients receiving the recommended dose at week 24. The median treatment duration was 6.0 months (range, 0.1–13.0 months). Among patients with available spleen assessments, 16/25 (64.0%) achieved ≥20% reduction in spleen index, with a median reduction of 24.0% (IQR, 7.4–40.6%). In patients achieving an anytime spleen response, 73.3% (11/15) also achieved symptom response. Symptom response was observed in 26/47 (55.3%) patients at week 12 and maintained in 26/45 (57.8%) patients at week 48 according to TSS50 criteria. Among 40 evaluable patients for anemia response, 18 (45.0%) achieved major anemia response and 9 (22.5%) achieved minor anemia response according to updated ELN criteria. Among patients with baseline hemoglobin <80 g/L, mean hemoglobin levels increased from 61 g/L at baseline to 85 g/L at week 12 and remained stable at 83 g/L at week 24. In contrast, patients with baseline hemoglobin ≥80 g/L maintained stable(105 g/L at baseline and 116 g/L at week 24). In exploratory analyses of predictors of symptom response, younger age was independently associated with a higher likelihood of achieving TSS50 at week 24 (OR, 0.89; 95% CI, 0.80–0.99; P=0.029), whereas higher baseline white blood cell count was independently associated with increased probability of symptom response (OR, 1.33; 95% CI, 1.01–1.76; P=0.045). For anemia response, JAK2 V617F mutation status was independently associated with major anemia response (JAK2 wild-type vs mutant: OR, 0.02; 95% CI, 0.00–0.50; P=0.016), and younger age at diagnosis was also associated with increased likelihood of achieving major anemia response (age ≥65 years vs <65 years: OR, 0.03; 95% CI, 0.00–0.59; P=0.021). The most common treatment-emergent adverse events (TEAEs) were anemia (17/55, 30.9%), fever (8/55, 14.5%), and infections (5/55, 9.1%). Grade 3/4 hematologic toxicities included anemia in 6 patients (10.9%) and thrombocytopenia in 5 patients (9.1%).
Conclusion: Gecacitinib demonstrated multidimensional clinical benefits, including symptom control and clinically meaningful hematologic improvement, in heavily pretreated patients with MF after ruxolitinib failure. Notably, hematologic improvement was observed even among patients with severe baseline anemia. Baseline age and white blood cell count were associated with symptom response, while age and JAK2 V617F mutation status were associated with major anemia response.
Acknowledgement: This research was supported by the National Natural Science Foundation of China (No. 82570191) and the Zhejiang Provincial Health High level Innovative Talent Project (2022-2026).
*Correspondence to: Jian Huang, M.D., Ph.D., Department of Hematology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang, China. E-mail: househuang@zju.edu.cn
DISCLOSURES
Jian Huang, MD, PhD: No relevant conflicts of interest to declare.